CommercialCoverageMedium impact
Sufentanil Sublingual Tablet (Dsuvia) (CPB 0944, reviewed 2025-12-09)
Aetna·Emergency Medicine, Anesthesiology, Pain Management +3 more·Medical Policy
Effective date
Dec 9, 2025
We identified it
Aug 17, 2026
Summary
Aetna has issued a new policy (effective immediately) designating Sufentanil Sublingual Tablet (Dsuvia) as NOT medically necessary for acute pain management and experimental/investigational for all other indications. This is a denial policy—claims for Dsuvia will not be covered under Aetna commercial plans regardless of clinical scenario.
Action Required
Immediately: Billing team must update claim denial protocols in billing system to automatically deny all Dsuvia claims submitted to Aetna commercial plans with denial reason: 'Not medically necessary per CPB 0944.' Providers must be notified via bulletin that Dsuvia is not a covered medication under Aetna and should not be prescribed for Aetna members seeking reimbursement. Add flag to encounter forms for Aetna patients: 'Dsuvia not covered—discuss alternative opioid options.' Any claims for Dsuvia submitted to Aetna will be denied; coordinate with providers to shift to covered acute pain alternatives (IV opioids, epidural analgesia, non-opioid analgesics). Revenue cycle team should expect denials and prepare patient communication templates for out-of-pocket cost notification.